Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction
1 other identifier
observational
459
1 country
1
Brief Summary
Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2014
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2014
CompletedFirst Submitted
Initial submission to the registry
February 3, 2014
CompletedFirst Posted
Study publicly available on registry
February 4, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedJune 20, 2014
June 1, 2014
4 months
February 3, 2014
June 19, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Periprocedural myocardial injury (MI)
Periprocedural MI was defined as cardiac Troponin I release \[5 times ULN\] 24 hours after percutaneous coronary intervention
24 hours after (percutaneous coroary intervention) PCI
Secondary Outcomes (1)
Periprocedural myonecrosis
24 hours after PCI
Other Outcomes (1)
inflammatory marker
24 hours after PCI
Eligibility Criteria
Metabolic syndorme (MS) was defined as the presence of 3 or more of these components: 1. high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose) 2. abdominal obesity (given as waist circumference \>102 cm in men and \>88 cm in women) 3. high blood pressure (\>130/\>85 mmHg or drug treatment for hypertension) 4. hypertriglyceridemia (serum triglycerides ≥150 mg/dl) 5. low high-density lipoprotein (HDL) cholesterol (\<40 mg/dl in men and \<50 mg/dl in women).
You may qualify if:
- metabolic syndrome
- elective percutaneous coronary intervention with angiographically successful stent implantation
You may not qualify if:
- acute coronary events
- renal failure
- needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
- left main coronary artery disease
- chronic total occlusion
- high levels of baseline CKMB or troponin
- any contraindication of aspirin, clopidogrel or ACEi treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ankara University School Of Medicine, Department of Cardiology
Ankara, 06230, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
February 3, 2014
First Posted
February 4, 2014
Study Start
February 1, 2014
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
June 20, 2014
Record last verified: 2014-06